Talis Biomedical Corporation (TLIS)

Talis Biomedical Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-62.01	-113.01	-192.04	-91.13	-27.47
Depreciation & Amortization	0.77	8.83	1.58	0.76	0.73
Asset Writedown & Restructuring Costs	2.77	3.59	-	-	-
Stock-Based Compensation	4.35	5.37	9.21	3.68	0.97
Other Operating Activities	4.3	2.77	1.04	0.61	0.82
Change in Accounts Receivable	0.26	-0.13	0.29	1.33	0.19
Change in Accounts Payable	-2.43	-1.19	0.22	3.2	0.19
Change in Other Net Operating Assets	-1.25	-6.37	8.32	-5.49	0.26
Operating Cash Flow	-53.24	-100.14	-171.38	-87.02	-24.33
Capital Expenditures	-0.49	-1.62	-2.87	-8.2	-0.58
Investing Cash Flow	-0.49	-1.62	-2.87	-8.2	-0.58
Short-Term Debt Issued	-	-	-	-	15
Total Debt Issued	-	-	-	-	15
Net Debt Issued (Repaid)	-	-	-	-	15
Issuance of Common Stock	0.03	0.41	234.43	0.02	0.02
Other Financing Activities	-	-	-	-1.45	-
Financing Cash Flow	0.03	0.41	234.43	246.75	39.61
Net Cash Flow	-53.69	-101.35	60.18	151.53	14.71
Free Cash Flow	-53.73	-101.75	-174.25	-95.23	-24.9
Free Cash Flow Margin	-2517.62%	-2114.53%	-2126.82%	-870.59%	-626.20%
Free Cash Flow Per Share	-29.56	-56.51	-115.37	-673.66	-173.70
Levered Free Cash Flow	-36.33	-65.56	-62.76	-97.18	-14.97
Unlevered Free Cash Flow	-36.33	-65.56	-62.76	-97.18	-14.97
Change in Net Working Capital	0.94	8.43	-49.21	36.44	-0.61

Source: S&P Global Market Intelligence. Standard template. Financial Sources.